Objective To study curative efficacy of salmeterol xinafoate and fluticasone propionate powder for inhalation combined with thymopentin in treatment of chronic obstructive pulmonary disease (COPD) and its effects on serum Interleukins (IL)8, complement C1q/tumor necrosis factor related protein (CTRP)-4, CTRP-5. Methods 92 patients of COPD received therapy from October 2015 to October 2017 in our hospital were selected as research objects. According to random number table，those patients were divided into the observation group (n=46) and the control group (n=46). On the basis of routine treatment, the control group was treated with salmeterol xinafoate and fluticasone propionate powder for inhalation, while the observation group was combined with thymopentin. They were treated continuously for 8 weeks. The clinical efficacy, the changes of pulmonary function［1 second forced expiratory volume (FEV1), FEV1/ forced vital capacity (FVC), maximum expiratory flow (PEF)］, immune function (T lymphocyte subsets CD+3, CD+4, CD+4/ CD+8) and serum IL8, CTRP4 and CTRP5 before and after treatment between the two groups were compared. The adverse drug reactions were observed. Results After treatment, the total effective rate of clinical efficacy in the observation group was was significantly higher than that of the control group (P＜0.05). After treatment, the FEV1, FEV1/FVC and PEF of two groups were significantly higher than those before treatment (P＜0.05), and the FEV1, FEV1/FVC and PEF in the observation group were higher than those in the control group(P＜0.05). After treatment, the CD+3, CD+4, CD+4/ CD+8 of two groups were significantly higher than those before treatment(P＜005), and the CD+3, CD+4, CD+4/ CD+8 in the observation group were higher than those in the control group(P＜0.05). After treatment, the serum IL-8, CTRP-4 and CTRP5 in the two groups were significantly lower than those before the treatment(P＜0.05), and the serum IL-8, CTRP-4 and CTRP-5 in the observation group were lower than those in the control group(P＜0.05). The total incidence of nausea and vomiting, abdominal pain, headache and loss of appetite during the treatment of the two groups was no significant difference(P＞0.05). Conclusion Salmeterol xinafoate and fluticasone propionate powder for inhalation can reduce the expression of serum IL-8, CTRP-4 and CTRP-5, improve the immune function and promote the recovery of lung function.